The article in Seeking Alpha was written by a venture capital executive of the above company. The company was founded on August 3, 2012 in Reno, NV (where gambling is legal). To quote from their intro statement:
"Enhydris Private Equity, Inc. pursues a venture capital investment strategy and seeks to buy large stakes in start-up companies developing revolutionary new technologies, or operating in emerging markets." These guys have no experience and are probably not invested in many companies. Like the donut eating cop from NJ that posts on Seeking Alpha about INSM, this is probably not worth the effort go get caught up in controversy. I read the article and the important part about INO's vaccine is the broad spectrum of antibody response. Besides the ADXS preparation acts by immune modulation, not antibody secretion. Apples and oranges. But this case is like the contest for EPO between Amgen and Genetics Institute. The fought it out in court while the Judge kept saying, "Cross license each other's technology and save more anemic people." GI said no and eventually lost all rights to EPO.
I am interested in the Hep C vaccine and am watching it closely. Also, there is a huge market for this technology in the veterinary market, but that always is a back seat opportunity.